Loading...

We've got a brand new version of Simply Wall St! Try it out

Health Sciences Acquisitions

Nasdaq:HSAC
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HSAC
Nasdaq
$32M
Market Cap
  1. Home
  2. US
  3. Diversified Financials
Company description

Health Sciences Acquisitions Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The last earnings update was 215 days ago. More info.


Add to Portfolio Compare Print
HSAC Share Price and Events
7 Day Returns
0.3%
NasdaqCM:HSAC
1%
US Capital Markets
0.7%
US Market
1 Year Returns
-
NasdaqCM:HSAC
8.6%
US Capital Markets
12.9%
US Market
HSAC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Health Sciences Acquisitions (HSAC) 0.3% 0.4% - - - -
US Capital Markets 1% 6.3% 8.3% 8.6% 34.7% 60.2%
US Market 0.7% 4.4% 7.2% 12.9% 39.5% 44.7%
1 Year Return vs Industry and Market
  • No trading data on HSAC.
  • No trading data on HSAC.

Value

 Is Health Sciences Acquisitions undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Health Sciences Acquisitions. This is due to cash flow or dividend data being unavailable. The share price is $10.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Health Sciences Acquisitions's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Health Sciences Acquisitions's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:HSAC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD Not available
NasdaqCM:HSAC Share Price ** NasdaqCM (2019-11-15) in USD $10.2
United States of America Capital Markets Industry PE Ratio Median Figure of 84 Publicly-Listed Capital Markets Companies 35.43x
United States of America Market PE Ratio Median Figure of 2,920 Publicly-Listed Companies 18.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Health Sciences Acquisitions.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Health Sciences Acquisitions, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Health Sciences Acquisitions's expected growth come at a high price?
Raw Data
NasdaqCM:HSAC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Capital Markets Industry PEG Ratio Median Figure of 38 Publicly-Listed Capital Markets Companies 2.02x
United States of America Market PEG Ratio Median Figure of 2,029 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Health Sciences Acquisitions, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Health Sciences Acquisitions's assets?
Raw Data
NasdaqCM:HSAC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD Not available
NasdaqCM:HSAC Share Price * NasdaqCM (2019-11-15) in USD $10.2
United States of America Capital Markets Industry PB Ratio Median Figure of 155 Publicly-Listed Capital Markets Companies 6.4x
United States of America Market PB Ratio Median Figure of 5,080 Publicly-Listed Companies 1.74x
NasdaqCM:HSAC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:HSAC Share Price ÷ Book Value per Share (both in USD)

= 10.2 ÷ 0.01

1038.7x

* Primary Listing of Health Sciences Acquisitions.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Health Sciences Acquisitions is overvalued based on assets compared to the US Capital Markets industry average.
X
Value checks
We assess Health Sciences Acquisitions's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. Health Sciences Acquisitions has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Health Sciences Acquisitions expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Health Sciences Acquisitions has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.4%
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Health Sciences Acquisitions expected to grow at an attractive rate?
  • Unable to compare Health Sciences Acquisitions's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Health Sciences Acquisitions's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Health Sciences Acquisitions's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:HSAC Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 5.4%
United States of America Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 3.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:HSAC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:HSAC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Health Sciences Acquisitions is high growth as no earnings estimate data is available.
  • Unable to determine if Health Sciences Acquisitions is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:HSAC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Health Sciences Acquisitions Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:HSAC Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Health Sciences Acquisitions will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Health Sciences Acquisitions's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Diversified Financials companies here
  2. Health Sciences Acquisitions's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Health Sciences Acquisitions's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Health Sciences Acquisitions has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Health Sciences Acquisitions performed over the past 5 years?

  • Health Sciences Acquisitions's last earnings update was 215 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Health Sciences Acquisitions's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Health Sciences Acquisitions does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Health Sciences Acquisitions's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Health Sciences Acquisitions's 1-year growth to the US Capital Markets industry average as it is not currently profitable.
Earnings and Revenue History
Health Sciences Acquisitions's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Health Sciences Acquisitions Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:HSAC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -0.01 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Health Sciences Acquisitions has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Health Sciences Acquisitions has efficiently used its assets last year compared to the US Capital Markets industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Health Sciences Acquisitions improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Health Sciences Acquisitions's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Health Sciences Acquisitions has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Health Sciences Acquisitions's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Health Sciences Acquisitions's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Health Sciences Acquisitions's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Health Sciences Acquisitions has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Health Sciences Acquisitions's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Health Sciences Acquisitions Company Filings, last reported 10 months ago.

NasdaqCM:HSAC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 0.02 0.30 0.33
  • Health Sciences Acquisitions's level of debt (1221.9%) compared to net worth is high (greater than 40%).
  • Unable to establish if Health Sciences Acquisitions's debt level has increased without past 5-year debt data.
  • Debt is not well covered by operating cash flow (0%, less than 20% of total debt).
  • Unable to confirm if the interest payments on Health Sciences Acquisitions's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Health Sciences Acquisitions's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Health Sciences Acquisitions has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Health Sciences Acquisitions's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Health Sciences Acquisitions dividends.
If you bought $2,000 of Health Sciences Acquisitions shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Health Sciences Acquisitions's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Health Sciences Acquisitions's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:HSAC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 43 Stocks 2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1953 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Health Sciences Acquisitions has not reported any payouts.
  • Unable to verify if Health Sciences Acquisitions's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Health Sciences Acquisitions's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Health Sciences Acquisitions has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Health Sciences Acquisitions's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Health Sciences Acquisitions afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Health Sciences Acquisitions has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Health Sciences Acquisitions's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rod Wong
AGE 42
TENURE AS CEO 0.8 years
CEO Bio

Dr. Roderick T. Wong, also known as Rod, MD, serves as Director at Landos Biopharma, Inc. He serves as President and Chief Executive Officer of Health Sciences Acquisitions Corp since January 2019 and its Director since December 2018. He serves as Managing Partner and Chief Investment Officer at RTW Investments LP. Dr. Wong founded the firm on March 1, 2010. He serves as Chairman of the Board of Health Sciences Acquisitions Corp. He has over a decade of experience as a life sciences Fund Manager. Prior to this, from March 2005 to January 2009, Dr. Wong was employed at Davidson Kempner Capital Management LLC. He started managing a healthcare book in 2005. Dr. Wong served as a Healthcare Analyst at Sigma Capital Management, LLC. He researched biotechnology companies at Cowen Group inc., where he served as an Executive Officer. Dr. Wong served as a Director at RXi Pharmaceuticals Corporation. He serves as the Chairman of Rocket Pharmaceuticals, Inc. since January 2018. He served as a Director of Penwest Pharmaceuticals Co. until 2010. Dr. Wong is an Adjunct Assistant Professor at the New York University Stern Business School. He has completed medical training. He simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School, and graduated Phi Beta Kappa with a BS in Economics from Duke University.

CEO Compensation
  • Insufficient data for Rod to compare compensation growth.
  • Insufficient data for Rod to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Health Sciences Acquisitions management team in years:

0.8
Average Tenure
43
Average Age
  • The average tenure for the Health Sciences Acquisitions management team is less than 2 years, this suggests a new team.
Management Team

Rod Wong

TITLE
President
AGE
42
TENURE
0.8 yrs

Naveen Yalamanchi

TITLE
Executive VP
AGE
42
TENURE
0.8 yrs

Alice Lee

TITLE
VP of Operations
AGE
48
TENURE
0.8 yrs

Stephanie Sirota

TITLE
VP of Corporate Strategy & Corporate Communications
AGE
44
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Health Sciences Acquisitions board of directors in years:

0.5
Average Tenure
48.5
Average Age
  • The average tenure for the Health Sciences Acquisitions board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rod Wong

TITLE
President
AGE
42

Naveen Yalamanchi

TITLE
Executive VP
AGE
42
TENURE
0.9 yrs

Pedro Granadillo

TITLE
Independent Director
AGE
71
TENURE
0.5 yrs

George Migausky

TITLE
Independent Director
AGE
65
TENURE
0.5 yrs

Sukumar Nagendran

TITLE
Independent Director
AGE
52
TENURE
0.5 yrs

Gotham Makker

TITLE
Independent Director
AGE
45
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Health Sciences Acquisitions's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Health Sciences Acquisitions has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Health Sciences Acquisitions Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the healthcare and healthcare-related industries in North America or Europe. The company was founded in 2018 and is based in New York, New York.

Details
Name: Health Sciences Acquisitions Corporation
HSAC
Exchange: NasdaqCM
Founded: 2018
$32,334,581
3,170,057
Website: http://
Address: Health Sciences Acquisitions Corporation
412 West 15th Street,
Floor 9,
New York,
New York, 10011,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM HSAC Common Stock Nasdaq Capital Market US USD 21. Jun 2019
NasdaqCM HSAC.U Units Nasdaq Capital Market US USD 10. May 2019
XNAS HSACU Units Nasdaq -All markets Floor US USD 10. May 2019
Number of employees
Current staff
Staff numbers
0
Health Sciences Acquisitions employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/17 00:48
End of day share price update: 2019/11/15 00:00
Last earnings filing: 2019/04/16
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.